Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 477736

Drug Profile

PF 477736

Alternative Names: PF-00477736; PF-477736; PF-736

Latest Information Update: 12 Apr 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Antineoplastics; Benzodiazepinones; Pyrazoles; Small molecules
  • Mechanism of Action Checkpoint kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 06 Apr 2011 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 102nd Annual Meeting of the American Association for Cancer Research (102nd-AACR-2011)
  • 27 Sep 2010 Discontinued - Phase-I for Solid tumours in Australia (IV)
  • 27 Sep 2010 Discontinued - Phase-I for Solid tumours in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top